Recommendation to switch patients on Femara from Fosamax to Zometa?


Question from LBoch: I had stage I breast cancer and was diagnosed with osteopenia. I am currently on Femara and alendronate and have maintained my bone density. I wanted to know if there are new recommendations to switch patients to zoledronic acid in light of recent studies.
Answers - Andrew D. Seidman, M.D. Alendronate (brand name: Fosamax) and zoledronate (brand name: Zometa) are both bisphosphonates that can prevent loss of bone density in women receiving aromatase inhibitors such as Femara. Zometa has been most rigorously studied for this benefit in clinical trials known as Z-Fast and Zo-Fast. Alendronate is an oral agent and Zometa is an intravenous drug. There are provocative data that suggest that Zometa may possibly also have a direct anti-tumor effect against breast cancer. We still await other confirmatory studies, however, before we can comfortably tell patients that the use of this class of drugs will prevent the recurrence of breast cancer when used in the adjuvant setting.

On Thursday, June 10, 2010, our Ask-the-Expert Online Conference was called Updates from the 2010 ASCO Annual Meeting. Andrew Seidman, M.D. and Beth Baughman DuPree, M.D., F.A.C.S. answered your questions about the latest updates on breast cancer risk, screening techniques, treatment options, and more.

The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.

A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.

Was this resource helpful?

Yes No
C3a
C3b
Evergreen-donate
Back to Top